HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mazor-Aronovitch, K Articles by Landau, H Search for Related Content PubMed PubMed Citation Articles by Mazor-Aronovitch, K Articles by Landau, H

Long-term neurodevelopmental outcome in conservatively treated congenital hyperinsulinism

Pediatric Endocrine Unit, Chaim Sheba Medical Center, Safra Children’s Hospital, Tel Hashomer 52621, Israel, ¹ Pediatric Endocrine and Metabolic Endocrine Units, Hadassah-Hebrew University Hospital, Jerusalem, Israel, ² Department of Pediatric Neurology, Schneider’s Children Medical Center, Petah Tiqva, Israel and ³ Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel

(Correspondence should be addressed to K Mazor-Aronovitch; Email: kineret{at}gmail.com)

Background: Congenital hyperinsulinism (CH) is treated surgically in many centers (near-total and partial pancreatectomy for diffuse and focal disease respectively). Most patients treated with near-total pancreatectomy developed diabetes during childhood/puberty. CH patients are at increased risk of neurodevelopmental disorders, some being severe, which are reported to occur in 14–44% of patients from highly heterogenous cohorts. Over the last few decades, we have treated children with CH conservatively without surgery. The aim of this study was to assess the neurodevelopmental outcome of these patients.

Design and methods: The study included 21 Ashkenazi CH medically treated patients: 11 homozygotes (diffuse disease) and 9 heterozygotes with mutations on the paternal allele (presumed focal disease). The mean age was 13.7 years (range 8–23). Neurodevelopmental outcomes were assessed by telephone interviews of parents, using a standard questionnaire. Closest age siblings of CH patients served as controls.

Results: Ten CH patients had perinatal seizures of short duration. Four had post-neonatal seizures, which remitted entirely. During early childhood, four patients (19%) had hypotonia, eight (38%) had fine motor problems, seven (33%) had gross motor problems (clumsiness), and one had mild cerebral palsy. Three patients (14%) had speech problems. Eight patients required developmental therapy, compared to one in the control group. Most of these problems were resolved by age 4–5 years. At school age, all were enrolled in regular education, some excelled in their studies, 6 out of 21 patients (29%) had learning problems (2 out of 21 controls). None had overt diabetes.

Conclusions: Good neurodevelopmental outcome was observed in our conservatively treated CH patients, with no diabetes as reported in patients undergoing pancreatectomy.

This article has been cited by other articles:

				H. B T Christesen, N. D Tribble, A. Molven, J. Siddiqui, T. Sandal, K. Brusgaard, S. Ellard, P. R Njolstad, J. Alm, B. Brock Jacobsen, et al. Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur. J. Endocrinol., July 1, 2008; 159(1): 27 - 34. [Abstract] [Full Text] [PDF]